Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...

Tyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $286.24 million, is garnering attention from investors and analysts alike as it advances its lead candidate, ...

The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

Sarcoidosis is a rare inflammatory condition that develops when groups of cells in your immune system form patches of swollen ...

More than 2,500 patients are currently waiting for that lifesaving transplant in Michigan. More than 100,000 are waiting ...

11 AP–HP, Hôpital Avicenne, Pulmonary Department and l'Université Paris 13, COMUE Sorbonne Paris Cité, EA 2363, Bobigny, France Background Sarcoidosis is a rare lung disease in children. The aim of ...

there is compelling evidence that those growing up with early life disadvantage are more likely to be diagnosed with occupational asthma and chronic obstructive pulmonary disease in adult life.8 In ...

Lung cancer screening aims to find lung cancer early. This is when there are more treatment options available and there is the best chance of treating it successfully. In the UK, the National ...

COPD is a progressive lung disease with mild symptoms in the early stages that gradually worsen. Early diagnosis and treatment can help preserve lung function. People with COPD often have trouble ...

People with COPD experience changes in their bodies. It starts with damage to the airways and tiny sacs in your lungs. That progresses to a wet cough and difficulty breathing, which can then get ...

(RTTNews) - aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, on Wednesday announced that it will present three important posters on efzofitimod at the American Thoracic Society or ...

The posters will cover the largest placebo-controlled trial in pulmonary sarcoidosis, real-world treatment patterns, and the incidence and mortality of the disease in the U.S. Efzofitimod ...